Table 1. Patient demographic and baseline characteristics.
| Baseline information | Result |
|---|---|
| Number of patients | 88 |
| Gender | |
| Male | 54 |
| Female | 34 |
| Age (years) | |
| Median | 60 |
| Range | 36–79 |
| Disease process | |
| Initial diagnosis stage IV | 38 |
| Relapse stage IV | 50 |
| Metastasis site | |
| Abdominal cavity | 10 |
| Liver | 58 |
| Lung | 41 |
| Lymph nodes | 22 |
| Other | 17 |
| Primary tumor location | |
| Left colon | 62 |
| Right colon | 26 |
| RAS, BRAF gene mutation, n (%) | |
| All wild type | 16 (18.18) |
| Unknown | 52 (59.09) |
| KRAS | 19 (21.59) |
| BRAF | 1 (1.14) |
| Targeted drug use in previous therapies, n (%) | |
| Unused | 42 (47.73) |
| Bevacizumab | 34 (38.64) |
| Cetuximab | 9 (10.23) |
| Other | 3 (3.41) |
| Compatibilities of chemotherapy with pemetrexed, n (%) | |
| Pemetrexed + S-1 | 26 (29.54) |
| Pemetrexed + S-1 + Bevacizumab | 21 (23.86) |
| Pemetrexed + Capecitabine | 7 (7.95) |
| Pemetrexed | 6 (6.82) |
| Pemetrexed + Oxaliplatin | 5 (5.68) |
| Pemetrexed + Bevacizumab | 5 (5.68) |
| Other compatibility regimens | 18 (20.45) |
*, P<0.05.